Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper

Journal of Geriatric Oncology

Volumn 6, Issue 2, 2015, Pages 141-152

  Morrison, Vicki A ^a   Hamlin, Paul ^b   Soubeyran, Pierre ^c   Stauder, Reinhard ^d   Wadhwa, Punit ^a   Aapro, Matti ^e   Lichtman, Stuart ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Comorbidities; Elderly; Frailty; Geriatric assessment; Large cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN STIMULATING AGENT; FAS ANTIGEN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

AGE ADJUSTED LIFE EXPECTANCY; AGED; ALGORITHM; ANGIOGENESIS; APOPTOSIS; B LYMPHOCYTE DIFFERENTIATION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL PRACTICE; CLINICAL PROGNOSTIC MODEL; COMORBIDITY; COMPREHENSIVE GERIATRIC ASSESSMENT; CONGESTIVE HEART FAILURE; DEMENTIA; DEMOGRAPHY; ENDORGAN DYSFUNCTION; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; GENE EXPRESSION PROFILING; GERIATRIC ASSESSMENT; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMICAL ALGORITHM; INTERNATIONAL PROGNOSTIC MODEL; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LIFE EXPECTANCY; LOW RISK POPULATION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NET SURVIVAL; NONBIOLOGICAL MODEL; PATIENT CARE; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHYSICAL DISEASE BY BODY FUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUPPORTIVE CARE; SURVIVAL RATE; SURVIVAL TIME; ADVISORY COMMITTEE; AGE; CONSENSUS DEVELOPMENT; FRAIL ELDERLY; GERIATRICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; ONCOLOGY; PROCEDURES; PROGNOSIS; VERY ELDERLY;

ADVISORY COMMITTEES; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMORBIDITY; FRAIL ELDERLY; GERIATRIC ASSESSMENT; GERIATRICS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEDICAL ONCOLOGY; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84925248601     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2014.11.004     Document Type: Review

References (108)

1. Thieblemont C., Coiffier B. Lymphoma in older patients. J Clin Oncol 2007, 25:1916-1923.
2. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) April 2012, National Cancer Institute, Bethesda, MD, (http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site). N. Howlader, A.M. Noone, M. Krapcho, N. Neyman, R. Aminou, S.F. Altekruse (Eds.).
3. Smith A., Howell D., Patmore R., Jack A., Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011, 105:1684-1692.
4. Incidence des cancers en 2012 en France. Institut de Veille Sanitaire (Rapport à paraitre en 2013).
5. Monnereau A., Troussard X., Belot A., Guizard A.V., Woronoff A.S., Bara S., et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2013, 132:2378-2387.
6. Sant M., Allemani C., De A.R., et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008, 44:579-587.
7. Marcos-Gragera R., Allemani C., Tereanu C., et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica 2011, 96:720-728.
8. The Non-Hodgkin's Lymphoma Pathologic Classification Project National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982, 49:2112-2135.
9. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
10. Jaffe E.S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 2009, 523-531.
11. Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification. J Clin Oncol 2014, 32:3059-3067.
12. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010, 116:5103-5110.
13. Hofscheier A., Ponciano A., Bonzheim I., et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011, 24:1046-1054.
14. Cannizzo E.S., Clement C.C., Sahu R., et al. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics 2011, 74:2313-2323.
15. Sieburg H.B., Cho R.H., Dykstra B., et al. The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets. Blood 2006, 107:2311-2316.
16. Falandry C., Gilson E., Rudolph K.L. Are aging biomarkers clinically relevant in oncogeriatrics?. Crit Rev Oncol Hematol 2013, 85:257-265.
17. Campisi J., Vijg J. Does damage to DNA and other macromolecules play a role in aging? If so, how?. J Gerontol A Biol Sci Med Sci 2009, 64A:175-178.
18. A predictive model for aggressive non-Hodgkin's lymphoma The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993, 329:987-994.
19. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
20. Ziepert M., Hasenclever D., Kuhnt E., Glass B., Schmitz N., Prfeundschuh M., et al. J Clin Oncol 2010, 28:2372-2380.
21. Advani R.H., Chen H., Habermann T.M., Morrison V.A., Weller E.A., Fisher R.I., et al. Comparison of conventional prognostic indices in patients older than 60years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70years in an elderly prognostic index (E-IPI). Br J Haematol 2010, 151:143-151.
22. Ninan M.J., Wadhwa P.D., Gupta P. Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2011, 52:360-373.
23. Wilson K.S., Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C.A., Gill K.K., et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007, 48:1102-1109.
24. Mounier N., Briere J., Gisselbrecht C., Emile J.F., Lederlin P., Sebban C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003, 101:4279-4284.
25. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphoma. Blood 2000, 96:1921-1925.
26. Hara T., Tsurumi H., Goto N., et al. Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. J Cancer Res Clin Oncol 2009, 135:1421-1428.
27. Xu-Monette Z.Y., Wu L., Visco C., Tai Y.C., Tzankov A., Lui W., et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012, 120:3986-3996.
28. Miller T.P., Grogan T.M., Dahlberg S., Spier C.M., Braziel R.M., Banks P.M., et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994, 83:1460-1466.
29. Jerkeman M., Anderson H., Dictor M., Kvaloy S., Akerman M., Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Ann Hematol 2004, 83:414-419.
30. Winter J.N., Weller E.A., Horning S.J., Krajewska M., Variakojis D., Habermann T.M., et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006, 107:4207-4213.
31. Barrans S.L., Fenton J.A., Banham A., Owen R.G., Jack A.S. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004, 104:2933-2935.
32. Evens A.M., Sehn L.H., Farinha P., Nelson B.P., Raji A., Lu Y., et al. Hypoxia-inducible factor-1 (alpha) expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010, 28:1017-1024.
33. Gratzinger D., Advani R., Zhao S., Talreja N., Tibshirani R.J., Shyam R., et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol 2010, 148:235-244.
34. Savage K.J., Johnson N.A., Ben-Neriah S., Connors J.M., Sehn L.H., Farinha P., et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009, 114:3533-3537.
35. Horn H., Ziepert M., Becher C., Barth T.F., Bernd H.W., Feller A.C., et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013, 121:2253-2263.
36. Green T.M., Young K.H., Visco C., Xu-Monette Z.Y., Orazi A., Go R.S., et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. J Clin Oncol 2012, 30:3460-3467.
37. Liu Y., Hernandez A.M., Shibata D., et al. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A 1994, 91:8910-8914.
38. Cortopassi G., Liu Y., Hutchin T. Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Exp Gerontol 1996, 31:253-265.
39. Klapper W., Kreuz M., Kohler C.W., et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012, 119:1882-1887.
40. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
41. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
42. Lenz G., Wright G.W., Emre N.C., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105:13520-13525.
43. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
44. Mareschal S., Lanic H., Ruminy P., et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011, 96:1888-1890.
45. Fontan L., Yang C., Kabaleeswaran V., et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012, 22:812-824.
46. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
47. Choi W.W., Weisenburger D.D., Greiner T.C., Piris M.A., Banham A.H., Delabie J., et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009, 15:5494-5502.
48. Copie-Bergman C., Gaulard P., Leroy K., Briere J., Baia M., Jais J.P., et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009, 27:5573-5579.
49. Walter L.C., Covinsky K.E. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001, 285:2750-2756.
50. CDC/NCHS National Vital Statistics System http://www.cdc.gov/nchs/nvss.htm.
51. Statistic Austria http://www.statistik.at.
52. Welch H.G., Albertsen P.C., Nease R.F., Bubolz T.A., Wasson J.H. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996, 124:577-584.
53. Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006, 295:801-808.
54. Schonberg M.A., Davis R.B., McCarthy E.P., Marcantonio E.R. Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. J Gen Intern Med 2009, 24:1115-1122.
55. Janssen-Heijnen M.L., van Spronsen D.J., Lemmens V.E., et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005, 129:597-606.
56. Gomez H., Hidalgo M., Casanova L., et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 1998, 16:2065-2069.
57. Yancik R., Wesley M.N., Ries L.A., et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998, 82:2123-2134.
58. Pallis A.G., Fortpied C., Wedding U., Van Nes M.C., Penninckx B., Ring A., et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 2010, 46:1502-1513.
59. Sonnen R., Schmidt W.P., Kuse R., et al. Treatment results of aggressive B-non-Hodgkin's lymphoma in advanced age considering comorbidity. Br J Haematol 2002, 119:634-639.
60. Hershman D.L., McBride R.B., Eisenberger A., et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:3159-3165.
61. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G.W., Suter T.M., Anker S.D., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011, 13:1-10.
62. Aapro M., Bernard-Marty C., Brain E., Batist G., Erdkamp F., Krzemieniecki K., et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011, 22:257-267.
63. Thieblemont C., Grossoeuvre A., Houot R., et al. Non-Hodgkin's lymphoma in very elderly patients over 80years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008, 19:774-779.
64. Lim S.T., Hee S.W., Quek R., et al. Performance status is the single most important prognostic factor in lymphoma patients aged greater than 75 overriding other prognostic factors such as histology. Leuk Lymphoma 2008, 49:149-151.
65. Extermann M., Overcash J., Lyman G.H., et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16:1582-1587.
66. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
67. Satariano W.A., Ragland D.A. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994, 120:104-110.
68. Hurria A., Gupta S., Zauderer M., et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005, 104:1998-2005.
69. Lichtman S.M. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol 2006, 3:86-93.
70. Extermann M. Treating Patients Who Have Cognitive Disorders and Cancer 2005, 403-405. ASCO Educational Book.
71. Extermann M. Older patients, cognitive impairment, and cancer: an increasingly frequent triad. J Natl Compr Canc Netw 2005, 3:593-596.
72. Wolfson C., Wolfson D.B., Asgharian M., et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001, 344:1111-1116.
73. Kemeny M.M. Surgery in older patients. Semin Oncol 2004, 31:175-184.
74. Venook A., Klein C., Kastrissios H., et al. Phase I study of urinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy. Proc Annu Meet Am Soc Clin Oncol 2001, 20:293a.
75. Venook A.P., Egorin M.J., Rosner G.L., et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998, 16:1811-1819.
76. Venook A.P., Egorin M.J., Rosner G.L., et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000, 18:2780-2787.
77. Venook A.P., Enders Klein C., Fleming G., et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003, 14:1783-1790.
78. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009, 27:1800-1805.
79. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007, 25:3055-3060.
80. Nabhan C., Smith S.M., Helenowski I., Ramsdale E., Parsons B., Karmali R., et al. Analysis of very elderly (≥80years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2012, 156:196-204.
81. Lichtman S.M., Wildiers H., Launay-Vacher V., Steer C., Chatelut E., Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007, 43:14-34.
82. Launay-Vacher V., Chatelut E., Lichtman S.M., Wildiers H., Steer C. Aapro M; International Society of Geriatric Oncology. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007, 18:1314-1321.
83. Marx G.M., Blake G.M., Galani E., et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004, 15:291-295.
84. Launay-Vacher V., Chatelut E., Lichtman S., et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007, 18:1314-1321.
85. Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012, 82:51-77.
86. Hamlin P. Treatment of aggressive non-Hodgkin's and Hodgkin's lymphoma in older patients 2007, 295-299. ASCO Education Book.
87. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55:241-252.
88. Hurria A., Togawa K., Mohile S.G., Owusu C., Klepin H.D., Gross C.P., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29:3457-3465.
89. Winkelmann N., Petersen I., Kiehntopf M., et al. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011, 137:733-738.
90. Tucci A., Ferrari S., Bottelli C., et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009, 115:4547-4553.
91. Siegel A.B., Lachs M., Coleman M., et al. Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clin Lymphoma Myeloma 2006, 7:65-69.
92. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 2007, 14:7-12.
93. Balducci L., Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000, 35:147-154.
94. Balducci L., Stanta G. Cancer in the frail patient. A coming epidemic. Hematol Oncol Clin North Am 2000, 14:235-250.
95. Balducci L. Supportive care in elderly cancer patients. Curr Opin Oncol 2009, 21:310-317.
96. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-M156.
97. Extermann M., Boler I., Reich R., Lyman G.H., Brown R.H., DeFelice J., et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 2012, 118:3377-3386.
98. Kuderer N.M., Dale D.C., Crawford J., et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
99. Chrischilles E.A., Klepser D.G., Brooks J.M., et al. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy. Pharmacotherapy 2005, 25:668-675.
100. Lyman G.H., Kuderer N.M., Crawford J., et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011, 117:1917-1927.
101. Balducci L., Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 2004, 100:6-11.
102. Lyman G.H., Delgado D.J. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003, 98:2402-2409.
103. Lyman G.H., Morrison V.A., Dale D.C., et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003, 44:2069-2076.
104. Balducci L., Al-Halawani H., Charu V., et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007, 12:1416-1424.
105. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42:2433-2453.
106. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
107. Rizzo J.D., Brouwers M., Hurley P., et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010, 116:4045-4059.
108. Rizzo J.D., Brouwers M., Hurley P., et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010, 28:4996-5010.